| FDA Office of Clinical Pharmacology Announces Availability of 2020 Annual Report | | The U.S. Food and Drug Administration (FDA), Office of Clinical Pharmacology (OCP) announces the availability of the 2020 OCP Annual Report. OCP is a dynamic, purpose-driven organization dedicated to promoting and protecting global public health through the application of clinical pharmacology and translational medicine principles. The 2020 OCP Annual Report highlights OCP's efforts to improve public health by building and translating knowledge of drug-response into patient-centered regulatory decisions of the highest quality. In 2020, COVID-19 posed an unparalleled therapeutic challenge to which OCP served a vital role in our nation's response. In the midst of the pandemic, OCP staff worked tirelessly to ensure the continuity of all drug development programs, research efforts, policy initiatives, and communication channels, fulfilling its mission of advancing innovative new medicines and promoting therapeutic optimization and individualization. The OCP 2020 Annual Report provides our stakeholders a glimpse of OCP's accomplishments during this rapidly evolving crisis and time of profound public health need in the global community. Learn more about OCP's diverse functional responsibilities, dedicated and collaborative culture, 2020 achievements, and 2021 outlook at the following link: https://go.usa.gov/xsj7c. Past OCP annual reports can be found at: https://go.usa.gov/xd9fu. | | The Office of Clinical Pharmacology (OCP) is pleased to offer the e-mail subscription service Clinical Pharmacology Corner. This is a free service from FDA to provide occasional updates from OCP regarding newly approved therapies, new regulatory and scholarly publications, upcoming events and other items of interest. Subscribe today at https://public.govdelivery.com/accounts/USFDA/subscriber/topics and select Clinical Pharmacology Corner under Drugs. We always welcome your thoughts regarding the format, content, and utility of this communication. Comments may be sent via email to ocp@fda.hhs.gov. This communication was prepared by Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA. | | | |
No comments:
Post a Comment